Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical Investigation
J Clin Invest. 1997 May 15; 99(10): 2545–2553.
PMCID: PMC508096

Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression.


The increase in oral availability of felodipine and other commonly used medications when taken with grapefruit juice has been assumed to be due to inhibition of CYP3A4, a cytochrome P450 that is present in liver and intestine. To evaluate the effect of repeated grapefruit juice ingestion on CYP3A4 expression, 10 healthy men were given 8 oz of grapefruit juice three times a day for 6 d. Before and after receiving grapefruit juice, small bowel and colon mucosal biopsies were obtained endoscopically, oral felodipine kinetics were determined, and liver CYP3A4 activity was measured with the [14C N-methyl] erythromycin breath test in each subject. Grapefruit juice did not alter liver CYP3A4 activity, colon levels of CYP3A5, or small bowel concentrations of P-glycoprotein, villin, CYP1A1, and CYP2D6. In contrast, the concentration of CYP3A4 in small bowel epithelia (enterocytes) fell 62% (P = 0.0006) with no corresponding change in CYP3A4 mRNA levels. In addition, enterocyte concentrations of CYP3A4 measured before grapefruit juice consumption correlated with the increase in Cmax when felodipine was taken with either the 1st or the 16th glass of grapefruit juice relative to water (r = 0. 67, P = 0.043, and r = 0.71, P = 0.022, respectively). We conclude that a mechanism for the effect of grapefruit juice on oral felodipine kinetics is its selective downregulation of CYP3A4 in the small intestine.

Full Text

The Full Text of this article is available as a PDF (289K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Bailey DG, Spence JD, Munoz C, Arnold JM. Interaction of citrus juices with felodipine and nifedipine. Lancet. 1991 Feb 2;337(8736):268–269. [PubMed]
  • Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther. 1996 Apr;59(4):383–388. [PubMed]
  • Weber A, Jäger R, Börner A, Klinger G, Vollanth R, Matthey K, Balogh A. Can grapefruit juice influence ethinylestradiol bioavailability? Contraception. 1996 Jan;53(1):41–47. [PubMed]
  • Kupferschmidt HH, Ha HR, Ziegler WH, Meier PJ, Krähenbühl S. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther. 1995 Jul;58(1):20–28. [PubMed]
  • Ducharme MP, Provenzano R, Dehoorne-Smith M, Edwards DJ. Trough concentrations of cyclosporine in blood following administration with grapefruit juice. Br J Clin Pharmacol. 1993 Nov;36(5):457–459. [PMC free article] [PubMed]
  • Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther. 1995 May;57(5):485–491. [PubMed]
  • Edgar B, Regårdh CG, Johnsson G, Johansson L, Lundborg P, Löfberg I, Rönn O. Felodipine kinetics in healthy men. Clin Pharmacol Ther. 1985 Aug;38(2):205–211. [PubMed]
  • Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, Wacher VJ. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther. 1995 Nov;58(5):492–497. [PubMed]
  • Fromm MF, Busse D, Kroemer HK, Eichelbaum M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology. 1996 Oct;24(4):796–801. [PubMed]
  • Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS, Thummel KE. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther. 1996 Jul;60(1):14–24. [PubMed]
  • Guengerich FP, Brian WR, Iwasaki M, Sari MA, Bärnhielm C, Berntsson P. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J Med Chem. 1991 Jun;34(6):1838–1844. [PubMed]
  • Yun CH, Okerholm RA, Guengerich FP. Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab Dispos. 1993 May-Jun;21(3):403–409. [PubMed]
  • Guengerich FP. Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. Mol Pharmacol. 1988 May;33(5):500–508. [PubMed]
  • Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T, Kalow W, Gelboin HV, et al. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem. 1989 Jun 25;264(18):10388–10395. [PubMed]
  • Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994 Jul;270(1):414–423. [PubMed]
  • Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest. 1987 Oct;80(4):1029–1036. [PMC free article] [PubMed]
  • Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest. 1992 Nov;90(5):1871–1878. [PMC free article] [PubMed]
  • Guengerich FP, Kim DH. In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis. 1990 Dec;11(12):2275–2279. [PubMed]
  • Miniscalco A, Lundahl J, Regårdh CG, Edgar B, Eriksson UG. Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. J Pharmacol Exp Ther. 1992 Jun;261(3):1195–1199. [PubMed]
  • Edwards DJ, Bellevue FH, 3rd, Woster PM. Identification of 6',7'-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos. 1996 Dec;24(12):1287–1290. [PubMed]
  • Wang SX, Sutfin TA, Bärnhielm C, Regårdh CG. Contribution of the intestine to the first-pass metabolism of felodipine in the rat. J Pharmacol Exp Ther. 1989 Aug;250(2):632–636. [PubMed]
  • Kolars JC, Awni WM, Merion RM, Watkins PB. First-pass metabolism of cyclosporin by the gut. Lancet. 1991 Dec 14;338(8781):1488–1490. [PubMed]
  • Bailey DG, Arnold JM, Bend JR, Tran LT, Spence JD. Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. Br J Clin Pharmacol. 1995 Aug;40(2):135–140. [PMC free article] [PubMed]
  • Hostetler KA, Wrighton SA, Molowa DT, Thomas PE, Levin W, Guzelian PS. Coinduction of multiple hepatic cytochrome P-450 proteins and their mRNAs in rats treated with imidazole antimycotic agents. Mol Pharmacol. 1989 Mar;35(3):279–285. [PubMed]
  • Schmiedlin-Ren P, Benedict PE, Dobbins WO, 3rd, Ghosh M, Kolars JC, Watkins PB. Cultured adult rat jejunal explants as a model for studying regulation of CYP3A. Biochem Pharmacol. 1993 Sep 1;46(5):905–918. [PubMed]
  • Wrighton SA, Maurel P, Schuetz EG, Watkins PB, Young B, Guzelian PS. Identification of the cytochrome P-450 induced by macrolide antibiotics in rat liver as the glucocorticoid responsive cytochrome P-450p. Biochemistry. 1985 Apr 23;24(9):2171–2178. [PubMed]
  • Watkins PB, Wrighton SA, Maurel P, Schuetz EG, Mendez-Picon G, Parker GA, Guzelian PS. Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl Acad Sci U S A. 1985 Sep;82(18):6310–6314. [PubMed]
  • Bonkovsky HL, Hauri HP, Marti U, Gasser R, Meyer UA. Cytochrome P450 of small intestinal epithelial cells. Immunochemical characterization of the increase in cytochrome P450 caused by phenobarbital. Gastroenterology. 1985 Feb;88(2):458–467. [PubMed]
  • Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, Watkins PB. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos. 1994 Nov-Dec;22(6):947–955. [PubMed]
  • Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, Vandenbranden M. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol. 1990 Aug;38(2):207–213. [PubMed]
  • Cribb A, Nuss C, Wang R. Antipeptide antibodies against overlapping sequences differentially inhibit human CYP2D6. Drug Metab Dispos. 1995 Jul;23(7):671–675. [PubMed]
  • Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7735–7738. [PubMed]
  • Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. [PubMed]
  • Lown K, Kolars J, Turgeon K, Merion R, Wrighton SA, Watkins PB. The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther. 1992 Mar;51(3):229–238. [PubMed]
  • Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J Clin Invest. 1989 Feb;83(2):688–697. [PMC free article] [PubMed]
  • Turgeon DK, Leichtman AB, Lown KS, Normolle DP, Deeb GM, Merion RM, Watkins PB. P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients. Clin Pharmacol Ther. 1994 Sep;56(3):253–260. [PubMed]
  • Ahnoff M. Determination of felodipine in plasma by capillary gas chromatography with electron capture detection. J Pharm Biomed Anal. 1984;2(3-4):519–526. [PubMed]
  • Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell. 1986 Nov 7;47(3):381–389. [PubMed]
  • Hsing S, Gatmaitan Z, Arias IM. The function of Gp170, the multidrug-resistance gene product, in the brush border of rat intestinal mucosa. Gastroenterology. 1992 Mar;102(3):879–885. [PubMed]
  • Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog. 1995 Jul;13(3):129–134. [PubMed]
  • Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993 Mar 25;268(9):6077–6080. [PubMed]
  • Smit JJ, Schinkel AH, Mol CA, Majoor D, Mooi WJ, Jongsma AP, Lincke CR, Borst P. Tissue distribution of the human MDR3 P-glycoprotein. Lab Invest. 1994 Nov;71(5):638–649. [PubMed]
  • Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM, Watkins PB. CYP3A gene expression in human gut epithelium. Pharmacogenetics. 1994 Oct;4(5):247–259. [PubMed]
  • Lundahl J, Regårdh CG, Edgar B, Johnsson G. Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur J Clin Pharmacol. 1995;49(1-2):61–67. [PubMed]
  • Tierney DJ, Haas AL, Koop DR. Degradation of cytochrome P450 2E1: selective loss after labilization of the enzyme. Arch Biochem Biophys. 1992 Feb 14;293(1):9–16. [PubMed]
  • Tephly TR, Black KA, Green MD, Coffman BL, Dannan GA, Guengerich FP. Effect of the suicide substrate 3,5-diethoxycarbonyl-2,6-dimethyl-4-ethyl-1,4-dihydropyridine on the metabolism of xenobiotics and on cytochrome P-450 apoproteins. Mol Pharmacol. 1986 Jan;29(1):81–87. [PubMed]
  • Menard RH, Guenthner TM, Kon H, Gillette JR. Studies on the destruction of adrenal and testicular cytochrome P-450 by spironolactone. Requirement for the 7alpha-thio group and evidence for the loss of the heme and apoproteins of cytochrome P-450. J Biol Chem. 1979 Mar 10;254(5):1726–1733. [PubMed]
  • Hoensch HP, Steinhardt HJ, Weiss G, Haug D, Maier A, Malchow H. Effects of semisynthetic diets on xenobiotic metabolizing enzyme activity and morphology of small intestinal mucosa in humans. Gastroenterology. 1984 Jun;86(6):1519–1530. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation